Regenxbio Inc (NASDAQ:RGNX)’s share price gapped down prior to trading on Monday . The stock had previously closed at $39.65, but opened at $35.20. Regenxbio shares last traded at $27.85, with a volume of 2384100 shares changing hands.

Several equities analysts recently issued reports on RGNX shares. BidaskClub raised Regenxbio from a “buy” rating to a “strong-buy” rating in a research report on Friday, December 22nd. Morgan Stanley reissued an “overweight” rating and issued a $34.00 target price on shares of Regenxbio in a research report on Thursday, November 9th. Chardan Capital reissued a “buy” rating on shares of Regenxbio in a research report on Monday, December 11th. Bank of America upped their target price on Regenxbio from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, September 21st. Finally, Zacks Investment Research downgraded Regenxbio from a “buy” rating to a “hold” rating in a research report on Friday, November 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $42.43.

The company has a market cap of $826.91 and a PE ratio of -9.80.

Regenxbio (NASDAQ:RGNX) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.04. Regenxbio had a negative return on equity of 39.33% and a negative net margin of 764.06%. The firm had revenue of $1.34 million for the quarter. analysts anticipate that Regenxbio Inc will post -2.71 earnings per share for the current fiscal year.

In other Regenxbio news, CFO Vittal Vasista sold 5,000 shares of the stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $33.25, for a total transaction of $166,250.00. Following the sale, the chief financial officer now directly owns 92,283 shares of the company’s stock, valued at approximately $3,068,409.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Curran Simpson sold 2,000 shares of the stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $29.31, for a total value of $58,620.00. Following the sale, the senior vice president now directly owns 41,500 shares in the company, valued at $1,216,365. The disclosure for this sale can be found here. Insiders have sold a total of 114,000 shares of company stock worth $3,646,446 over the last ninety days. 17.00% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Citigroup Inc. grew its position in Regenxbio by 1,042.8% during the 2nd quarter. Citigroup Inc. now owns 29,348 shares of the biotechnology company’s stock worth $580,000 after purchasing an additional 26,780 shares during the period. Goldman Sachs Group Inc. grew its position in Regenxbio by 222.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 113,906 shares of the biotechnology company’s stock worth $2,250,000 after purchasing an additional 78,606 shares during the period. TIAA CREF Investment Management LLC grew its position in Regenxbio by 33.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 74,175 shares of the biotechnology company’s stock worth $1,465,000 after purchasing an additional 18,647 shares during the period. Redmile Group LLC grew its position in Regenxbio by 35.4% during the 2nd quarter. Redmile Group LLC now owns 1,718,671 shares of the biotechnology company’s stock worth $33,944,000 after purchasing an additional 449,540 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its position in shares of Regenxbio by 32.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 97,695 shares of the biotechnology company’s stock valued at $1,930,000 after acquiring an additional 23,971 shares during the period. 68.73% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Regenxbio (RGNX) Shares Gap Down to $35.20” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/regenxbio-rgnx-shares-gap-down-to-35-20/1798844.html.

About Regenxbio

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with Analyst Ratings Network's FREE daily email newsletter.